Christian Jackisch Selected Research

Epirubicin (Ellence)

1/2022	Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.
1/2020	Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial.
1/2019	NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto.
1/2019	Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
1/2018	Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
3/2016	Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
10/2015	A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
7/2015	Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).
7/2013	Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial.
7/2013	Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christian Jackisch Research Topics

Disease

128	Breast Neoplasms (Breast Cancer) 02/2022 - 04/2002
41	Neoplasms (Cancer) 11/2022 - 10/2002
13	Pathologic Complete Response 05/2021 - 04/2010
11	Triple Negative Breast Neoplasms 01/2022 - 09/2013
9	Ovarian Neoplasms (Ovarian Cancer) 01/2020 - 09/2003
7	Neutropenia 01/2021 - 09/2006
6	Carcinoma (Carcinomatosis) 10/2017 - 12/2003
6	Exanthema (Rash) 01/2016 - 04/2007
5	Diarrhea 10/2021 - 04/2007
5	Cardiotoxicity 06/2021 - 10/2005
5	Febrile Neutropenia 01/2021 - 11/2008
5	Infections 07/2015 - 03/2009
4	Neoplasm Metastasis (Metastasis) 10/2021 - 08/2006
4	Ovarian Epithelial Carcinoma 01/2017 - 08/2006
3	Inflammatory Breast Neoplasms 11/2019 - 01/2010
3	Cardiovascular Diseases (Cardiovascular Disease) 05/2019 - 09/2013
3	Hand-Foot Syndrome 01/2012 - 04/2010
3	Noninfiltrating Intraductal Carcinoma (DCIS) 02/2006 - 10/2004
2	Brain Neoplasms (Brain Tumor) 02/2022 - 01/2010
2	Heart Failure 03/2016 - 03/2010
2	Thrombocytopenia (Thrombopenia) 06/2014 - 07/2013
2	Lobular Carcinoma 02/2014 - 06/2013
2	Hypertension (High Blood Pressure) 09/2013 - 01/2012
2	Disease Progression 01/2006 - 10/2004
1	Body Weight (Weight, Body) 06/2021
1	Overweight 06/2021
1	Premature Birth (Birth, Premature) 02/2021
1	Myocardial Infarction 01/2021
1	Thrombocytosis (Thrombocythemia) 01/2020
1	Autoimmune Diseases (Autoimmune Disease) 02/2019
1	Amenorrhea 01/2019
1	Residual Neoplasm 01/2019

Drug/Important Bio-Agent (IBA)

39	Trastuzumab (Herceptin)FDA Link 01/2022 - 10/2004
24	Hormones (Hormone)IBA 01/2022 - 04/2005
22	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 09/2003
22	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 10/2002
22	human ERBB2 proteinIBA 10/2021 - 01/2006
21	taxaneIBA 01/2021 - 01/2006
17	Epirubicin (Ellence)FDA LinkGeneric 01/2022 - 03/2010
15	AnthracyclinesIBA 01/2021 - 01/2009
13	Lapatinib (GW572016)FDA Link 01/2021 - 01/2010
12	Docetaxel (Taxotere)FDA Link 01/2018 - 10/2002
10	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 09/2003
8	130-nm albumin-bound paclitaxelIBA 01/2022 - 04/2012
8	ErbB Receptors (EGF Receptor)IBA 10/2021 - 03/2010
8	Capecitabine (Xeloda)FDA Link 10/2021 - 04/2008
8	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2013 - 10/2002
7	PlatinumIBA 01/2020 - 10/2006
6	pertuzumabIBA 01/2022 - 03/2013
6	Phenobarbital (Luminal)FDA Link 10/2019 - 05/2012
6	Estrogen ReceptorsIBA 01/2018 - 10/2004
6	Bevacizumab (Avastin)FDA Link 10/2017 - 01/2012
5	Progesterone Receptors (Progesterone Receptor)IBA 01/2018 - 10/2004
5	Tamoxifen FDA LinkGeneric 12/2008 - 10/2002
4	liposomal doxorubicin (Doxil)FDA Link 01/2022 - 07/2010
4	Biomarkers (Surrogate Marker)IBA 05/2021 - 01/2008
3	Epidermal Growth Factor (EGF)IBA 10/2021 - 02/2014
3	Immunoconjugates (Immunoconjugate)IBA 05/2021 - 01/2019
3	Aromatase InhibitorsIBA 06/2020 - 02/2007
3	Cytotoxins (Cytolysins)IBA 01/2019 - 10/2004
3	AlbuminsIBA 01/2019 - 03/2009
3	Monoclonal AntibodiesIBA 01/2017 - 10/2005
3	Proteins (Proteins, Gene)FDA Link 01/2016 - 02/2006
3	Vinorelbine (Navelbine)FDA LinkGeneric 08/2013 - 04/2008
2	Immune Checkpoint InhibitorsIBA 05/2021 - 05/2021
2	Anastrozole (Arimidex)FDA LinkGeneric 06/2020 - 05/2013
2	Biological ProductsIBA 01/2020 - 08/2015
2	Ado-Trastuzumab EmtansineIBA 01/2019 - 04/2017
2	SolventsIBA 01/2019 - 03/2016
2	Biosimilar PharmaceuticalsIBA 04/2017 - 01/2015
2	Indicators and Reagents (Reagents)IBA 04/2017 - 12/2010
2	ParaffinIBA 10/2016 - 02/2006
2	Pharmaceutical PreparationsIBA 09/2014 - 04/2007
2	Ibandronic Acid (Boniva)FDA Link 10/2013 - 10/2011
2	AntibodiesIBA 03/2013 - 01/2009
2	Taxoids (Taxanes)IBA 04/2012 - 10/2004
2	Gemcitabine FDA Link 09/2010 - 10/2006
2	Tyrosine Kinase InhibitorsIBA 01/2010 - 01/2009
2	SteroidsIBA 01/2009 - 02/2006
2	Estrogen Receptor alphaIBA 03/2005 - 10/2004
1	Denosumab FDA Link 01/2022
1	neratinibIBA 10/2021
1	Cyclin-Dependent Kinase 4IBA 05/2021
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021
1	Maytansine (Maitansine)IBA 01/2019
1	antineoplaston A10 (A 10)IBA 01/2018

Therapy/Procedure

59	Therapeutics 11/2022 - 10/2004
49	Neoadjuvant Therapy 01/2022 - 10/2002
42	Drug Therapy (Chemotherapy) 10/2021 - 09/2003
9	Adjuvant Chemotherapy 01/2017 - 10/2005
4	Radiotherapy 10/2021 - 02/2011
3	Drug Tapering 04/2014 - 09/2006
2	Subcutaneous Injections 01/2022 - 01/2021
2	Operative Surgical Procedures 10/2021 - 11/2006
2	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 01/2018
2	Intravenous Infusions 01/2021 - 01/2016
2	Mastectomy (Mammectomy) 11/2019 - 01/2010
2	Aftercare (After-Treatment) 11/2018 - 10/2018
1	Palliative Care (Palliative Therapy) 02/2022
1	Pessaries 02/2021